Activity ratios measure how efficiently a company performs day-to-day tasks, such us the collection of receivables and management of inventory.
Paying user area
Try for free
Merck & Co. Inc. pages available for free this week:
- Income Statement
- Common-Size Income Statement
- Analysis of Profitability Ratios
- DuPont Analysis: Disaggregation of ROE, ROA, and Net Profit Margin
- Analysis of Geographic Areas
- Common Stock Valuation Ratios
- Enterprise Value (EV)
- Current Ratio since 2005
- Total Asset Turnover since 2005
- Aggregate Accruals
The data is hidden behind: . Unhide it.
Get full access to the entire website from $10.42/mo, or
get 1-month access to Merck & Co. Inc. for $24.99.
This is a one-time payment. There is no automatic renewal.
We accept:
Short-term Activity Ratios (Summary)
Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).
An examination of short-term operating activity ratios reveals several noteworthy trends between 2021 and 2025. Generally, the company demonstrates fluctuating efficiency in managing its short-term assets and liabilities. Inventory turnover initially improved but subsequently stabilized at a lower level, while receivables and payables turnover exhibited similar patterns of increase followed by stabilization. Working capital turnover showed significant volatility over the period.
- Inventory Management
- Inventory turnover increased from 2.29 in 2021 to 2.95 in 2022, indicating improved efficiency in converting inventory into sales. However, this improvement was not sustained, with the ratio declining to 2.46 by 2025. Correspondingly, the average inventory processing period decreased from 159 days in 2021 to 124 days in 2022, then gradually increased to 148 days in 2025, mirroring the inventory turnover trend. This suggests a potential slowing in the rate of inventory sales in recent years.
- Receivables Management
- Receivables turnover rose from 5.28 in 2021 to 6.27 in 2022, suggesting a more efficient collection of receivables. The ratio experienced a slight decline to 5.52 in 2025. The average receivable collection period decreased from 69 days in 2021 to 58 days in 2022, remaining relatively stable before increasing to 66 days in 2025. This indicates a slight lengthening in the time taken to collect receivables towards the end of the period.
- Payables Management
- Payables turnover increased from 2.96 in 2021 to 4.11 in 2023, indicating the company paid its suppliers more frequently. The ratio then decreased to 3.72 in both 2024 and 2025. The average payables payment period decreased from 123 days in 2021 to 89 days in 2022 and 2023, before increasing to 98 days in 2024 and 2025. This suggests a potential shift in payment terms or supplier relationships.
- Overall Operating Cycle & Cash Conversion Cycle
- The operating cycle decreased from 228 days in 2021 to 182 days in 2022, then increased to 214 days in 2025. The cash conversion cycle followed a similar pattern, decreasing from 105 days in 2021 to 93 days in 2022, and then increasing to 116 days in 2025. These trends suggest an initial improvement in the efficiency of converting investments in inventory and receivables into cash, followed by a reversal of that improvement.
- Working Capital Utilization
- Working capital turnover experienced significant fluctuation, decreasing from 7.62 in 2021 to 5.16 in 2022, increasing sharply to 9.29 in 2023, then decreasing to 4.28 in 2025. This volatility suggests inconsistent efficiency in utilizing working capital to generate sales. The large swings warrant further investigation to understand the underlying drivers.
Turnover Ratios
Average No. Days
Inventory Turnover
| Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||
| Cost of sales | ||||||
| Inventories, excludes inventories classified in Other assets | ||||||
| Short-term Activity Ratio | ||||||
| Inventory turnover1 | ||||||
| Benchmarks | ||||||
| Inventory Turnover, Competitors2 | ||||||
| AbbVie Inc. | ||||||
| Amgen Inc. | ||||||
| Bristol-Myers Squibb Co. | ||||||
| Danaher Corp. | ||||||
| Eli Lilly & Co. | ||||||
| Gilead Sciences Inc. | ||||||
| Johnson & Johnson | ||||||
| Pfizer Inc. | ||||||
| Regeneron Pharmaceuticals Inc. | ||||||
| Thermo Fisher Scientific Inc. | ||||||
| Vertex Pharmaceuticals Inc. | ||||||
| Inventory Turnover, Sector | ||||||
| Pharmaceuticals, Biotechnology & Life Sciences | ||||||
| Inventory Turnover, Industry | ||||||
| Health Care | ||||||
Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).
1 2025 Calculation
Inventory turnover = Cost of sales ÷ Inventories, excludes inventories classified in Other assets
= ÷ =
2 Click competitor name to see calculations.
The inventory turnover ratio exhibited volatility over the five-year period. Initially, the ratio increased significantly before stabilizing and then experiencing a slight decline. Cost of sales demonstrated an overall increase, though with a decrease in one year, while inventory levels generally increased throughout the period.
- Inventory Turnover Trend
- The inventory turnover ratio rose from 2.29 in 2021 to 2.95 in 2022, indicating a more efficient conversion of inventory into sales. This improvement suggests enhanced inventory management or increased demand for products. However, the ratio subsequently decreased to 2.54 in 2023, and continued to decline modestly to 2.49 in 2024 and 2.46 in 2025. This recent downward trend could indicate slowing sales growth, increased inventory levels, or a combination of both.
- Cost of Sales Analysis
- Cost of sales increased from US$13,626 million in 2021 to US$17,411 million in 2022, aligning with the increase in the inventory turnover ratio. A decrease was observed in 2023, with cost of sales falling to US$16,126 million. Cost of sales then decreased again in 2024 to US$15,193 million before rising to US$16,382 million in 2025. These fluctuations in cost of sales may be attributable to changes in production volume, raw material costs, or manufacturing efficiency.
- Inventory Level Analysis
- Inventories, excluding those classified in Other assets, remained relatively stable between 2021 and 2022, fluctuating around US$5,900 million. A noticeable increase occurred in 2023, reaching US$6,358 million, and continued to rise to US$6,658 million in 2025. This consistent increase in inventory levels, coupled with the declining inventory turnover ratio in the later years, suggests a potential buildup of inventory that may require attention.
The combined trends suggest that while initial improvements in inventory management were observed, more recent performance indicates a potential weakening in the efficiency of inventory conversion. Further investigation into the factors driving the increase in inventory levels and the slight decline in sales may be warranted.
Receivables Turnover
| Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||
| Sales | ||||||
| Accounts receivable, net of allowance for doubtful accounts | ||||||
| Short-term Activity Ratio | ||||||
| Receivables turnover1 | ||||||
| Benchmarks | ||||||
| Receivables Turnover, Competitors2 | ||||||
| AbbVie Inc. | ||||||
| Amgen Inc. | ||||||
| Bristol-Myers Squibb Co. | ||||||
| Danaher Corp. | ||||||
| Eli Lilly & Co. | ||||||
| Gilead Sciences Inc. | ||||||
| Johnson & Johnson | ||||||
| Pfizer Inc. | ||||||
| Regeneron Pharmaceuticals Inc. | ||||||
| Thermo Fisher Scientific Inc. | ||||||
| Vertex Pharmaceuticals Inc. | ||||||
| Receivables Turnover, Sector | ||||||
| Pharmaceuticals, Biotechnology & Life Sciences | ||||||
| Receivables Turnover, Industry | ||||||
| Health Care | ||||||
Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).
1 2025 Calculation
Receivables turnover = Sales ÷ Accounts receivable, net of allowance for doubtful accounts
= ÷ =
2 Click competitor name to see calculations.
The receivables turnover ratio exhibits fluctuations over the five-year period. While generally remaining within a relatively narrow range, observable trends suggest shifts in the efficiency of collecting receivables.
- Overall Trend
- The receivables turnover ratio increased from 5.28 in 2021 to 6.27 in 2022, indicating improved efficiency in converting receivables into cash. This positive trend was partially reversed in 2023, with the ratio declining to 5.81. A slight recovery occurred in 2024, reaching 6.24, before decreasing again to 5.52 in 2025.
- Year-over-Year Changes
- The largest year-over-year increase in the receivables turnover ratio occurred between 2021 and 2022, representing an 18.75% improvement. The decrease from 2022 to 2023 was 7.32%, and the decrease from 2024 to 2025 was 11.25%. The increase from 2023 to 2024 was 7.03%.
- Relationship to Sales
- Sales demonstrated a consistent upward trend throughout the period, increasing from US$48,704 million in 2021 to US$65,011 million in 2025. Despite this sales growth, the receivables turnover ratio did not consistently increase, suggesting that the growth in accounts receivable partially offset the benefits of higher sales volume. The increase in accounts receivable from US$10,278 million in 2024 to US$11,775 million in 2025, coupled with a decrease in the turnover ratio, supports this observation.
The fluctuations in the receivables turnover ratio warrant further investigation. While the ratio remains at a generally acceptable level, the recent decline in 2025, despite continued sales growth, could indicate a potential slowdown in the collection process or a shift in credit terms offered to customers. Monitoring this trend in subsequent periods is recommended.
Payables Turnover
| Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||
| Cost of sales | ||||||
| Trade accounts payable | ||||||
| Short-term Activity Ratio | ||||||
| Payables turnover1 | ||||||
| Benchmarks | ||||||
| Payables Turnover, Competitors2 | ||||||
| AbbVie Inc. | ||||||
| Amgen Inc. | ||||||
| Bristol-Myers Squibb Co. | ||||||
| Danaher Corp. | ||||||
| Eli Lilly & Co. | ||||||
| Gilead Sciences Inc. | ||||||
| Johnson & Johnson | ||||||
| Pfizer Inc. | ||||||
| Regeneron Pharmaceuticals Inc. | ||||||
| Thermo Fisher Scientific Inc. | ||||||
| Vertex Pharmaceuticals Inc. | ||||||
| Payables Turnover, Sector | ||||||
| Pharmaceuticals, Biotechnology & Life Sciences | ||||||
| Payables Turnover, Industry | ||||||
| Health Care | ||||||
Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).
1 2025 Calculation
Payables turnover = Cost of sales ÷ Trade accounts payable
= ÷ =
2 Click competitor name to see calculations.
The analysis reveals fluctuations in payables turnover over the five-year period. While cost of sales generally increased, trade accounts payable exhibited a more variable pattern, influencing the observed turnover ratio.
- Payables Turnover Trend
- The payables turnover ratio increased from 2.96 in 2021 to 4.08 in 2022, indicating a more efficient use of credit from suppliers. This improvement suggests the company was quicker to pay its suppliers during this period, potentially benefiting from early payment discounts or improved supplier relationships. The ratio remained relatively stable between 2022 and 2023, at 4.11. A subsequent decrease to 3.72 was observed in both 2024 and 2025, suggesting a lengthening of the payment cycle or an increase in accounts payable relative to cost of sales.
- Cost of Sales and Payables Relationship
- Cost of sales increased from US$13,626 million in 2021 to US$17,411 million in 2022, coinciding with the initial increase in payables turnover. Despite a decrease in cost of sales to US$16,126 million in 2023, the payables turnover remained high. Cost of sales fluctuated between US$15,193 million and US$16,382 million for 2024 and 2025, respectively. Trade accounts payable decreased from US$4,609 million in 2021 to US$3,922 million in 2023, then increased to US$4,404 million in 2025. This interplay between cost of sales and trade accounts payable is a key driver of the observed trends in the payables turnover ratio.
The stabilization and subsequent decline in payables turnover in the later years warrants further investigation. Potential factors contributing to this trend could include changes in supplier terms, shifts in purchasing strategies, or alterations in the company’s working capital management policies.
Working Capital Turnover
| Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | ||||||
| Current assets | ||||||
| Less: Current liabilities | ||||||
| Working capital | ||||||
| Sales | ||||||
| Short-term Activity Ratio | ||||||
| Working capital turnover1 | ||||||
| Benchmarks | ||||||
| Working Capital Turnover, Competitors2 | ||||||
| AbbVie Inc. | ||||||
| Amgen Inc. | ||||||
| Bristol-Myers Squibb Co. | ||||||
| Danaher Corp. | ||||||
| Eli Lilly & Co. | ||||||
| Gilead Sciences Inc. | ||||||
| Johnson & Johnson | ||||||
| Pfizer Inc. | ||||||
| Regeneron Pharmaceuticals Inc. | ||||||
| Thermo Fisher Scientific Inc. | ||||||
| Vertex Pharmaceuticals Inc. | ||||||
| Working Capital Turnover, Sector | ||||||
| Pharmaceuticals, Biotechnology & Life Sciences | ||||||
| Working Capital Turnover, Industry | ||||||
| Health Care | ||||||
Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).
1 2025 Calculation
Working capital turnover = Sales ÷ Working capital
= ÷ =
2 Click competitor name to see calculations.
The working capital turnover ratio exhibits considerable fluctuation over the five-year period. Initial values demonstrate a relatively high level of efficiency in utilizing working capital, followed by periods of decreased and then increased activity. A detailed examination of the ratio’s behavior reveals notable shifts in the relationship between working capital and sales.
- Overall Trend
- The working capital turnover ratio does not demonstrate a consistent trend. It begins at 7.62, declines significantly, rises again, and then declines once more. This suggests changes in the company’s operational efficiency or strategic shifts in working capital management.
- 2021 to 2022
- A substantial decrease in the working capital turnover is observed from 2021 to 2022, moving from 7.62 to 5.16. This indicates a less efficient utilization of working capital in generating sales during 2022. This could be attributed to an increase in working capital relative to sales, potentially due to increased inventory levels, slower collection of receivables, or a combination of factors.
- 2022 to 2023
- The ratio experiences a significant recovery between 2022 and 2023, increasing to 9.29. This represents the highest turnover ratio within the observed period, suggesting improved efficiency in managing working capital and converting it into sales. The increase could be due to a decrease in working capital or a rise in sales, or a combination of both.
- 2023 to 2025
- From 2023 to 2025, the working capital turnover ratio declines from 9.29 to 4.28. This represents a considerable decrease, indicating a reduced efficiency in utilizing working capital. Despite an increase in sales from 60,115 to 65,011, the working capital also increased substantially, leading to the lower turnover ratio. This suggests a potential build-up of working capital components, possibly indicating slower sales conversion or increased investment in current assets.
- Working Capital and Sales Relationship
- The fluctuations in the working capital turnover ratio are closely linked to the changes in both working capital and sales. While sales generally increased over the period, the corresponding changes in working capital have a significant impact on the ratio. The largest decrease in turnover coincides with a substantial increase in working capital from 2021 to 2022, and the subsequent decrease from 2023 to 2025 is also linked to a significant increase in working capital.
In conclusion, the working capital turnover ratio demonstrates a volatile pattern, indicating inconsistent efficiency in utilizing working capital to generate sales. Further investigation into the underlying components of working capital – such as inventory, accounts receivable, and accounts payable – is recommended to understand the drivers behind these fluctuations.
Average Inventory Processing Period
| Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data | ||||||
| Inventory turnover | ||||||
| Short-term Activity Ratio (no. days) | ||||||
| Average inventory processing period1 | ||||||
| Benchmarks (no. days) | ||||||
| Average Inventory Processing Period, Competitors2 | ||||||
| AbbVie Inc. | ||||||
| Amgen Inc. | ||||||
| Bristol-Myers Squibb Co. | ||||||
| Danaher Corp. | ||||||
| Eli Lilly & Co. | ||||||
| Gilead Sciences Inc. | ||||||
| Johnson & Johnson | ||||||
| Pfizer Inc. | ||||||
| Regeneron Pharmaceuticals Inc. | ||||||
| Thermo Fisher Scientific Inc. | ||||||
| Vertex Pharmaceuticals Inc. | ||||||
| Average Inventory Processing Period, Sector | ||||||
| Pharmaceuticals, Biotechnology & Life Sciences | ||||||
| Average Inventory Processing Period, Industry | ||||||
| Health Care | ||||||
Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).
1 2025 Calculation
Average inventory processing period = 365 ÷ Inventory turnover
= 365 ÷ =
2 Click competitor name to see calculations.
The period under review demonstrates fluctuations in inventory management efficiency. Specifically, the average inventory processing period exhibited a decreasing trend initially, followed by a period of stabilization and slight increase. Inventory turnover showed an initial increase, then a decline, mirroring the changes in processing period.
- Average Inventory Processing Period
- In 2021, the average inventory processing period was 159 days. A significant decrease was observed in 2022, falling to 124 days, indicating improved efficiency in converting inventory into sales. This improvement did not continue, as the period increased to 144 days in 2023. The rate of increase slowed in subsequent years, with the period reaching 147 days in 2024 and 148 days in 2025. This suggests a stabilization of inventory processing time, albeit at a higher level than observed in 2022. The recent trend indicates a potential challenge in maintaining the efficiency gains achieved in 2022.
- Inventory Turnover
- Inventory turnover increased from 2.29 in 2021 to 2.95 in 2022, aligning with the reduced average inventory processing period. This suggests that inventory was being sold more quickly. However, turnover decreased to 2.54 in 2023, and continued to decline, reaching 2.46 in 2025. This decrease in turnover corresponds with the lengthening of the average inventory processing period, indicating a slower rate of inventory depletion. The consistent decline from 2022 suggests a potential weakening in sales relative to inventory levels.
The combined trends suggest that while initial improvements were made in inventory management, the company has experienced a reversal in efficiency. Further investigation may be warranted to understand the factors contributing to the stabilization and slight increase in the average inventory processing period and the corresponding decline in inventory turnover.
Average Receivable Collection Period
| Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data | ||||||
| Receivables turnover | ||||||
| Short-term Activity Ratio (no. days) | ||||||
| Average receivable collection period1 | ||||||
| Benchmarks (no. days) | ||||||
| Average Receivable Collection Period, Competitors2 | ||||||
| AbbVie Inc. | ||||||
| Amgen Inc. | ||||||
| Bristol-Myers Squibb Co. | ||||||
| Danaher Corp. | ||||||
| Eli Lilly & Co. | ||||||
| Gilead Sciences Inc. | ||||||
| Johnson & Johnson | ||||||
| Pfizer Inc. | ||||||
| Regeneron Pharmaceuticals Inc. | ||||||
| Thermo Fisher Scientific Inc. | ||||||
| Vertex Pharmaceuticals Inc. | ||||||
| Average Receivable Collection Period, Sector | ||||||
| Pharmaceuticals, Biotechnology & Life Sciences | ||||||
| Average Receivable Collection Period, Industry | ||||||
| Health Care | ||||||
Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).
1 2025 Calculation
Average receivable collection period = 365 ÷ Receivables turnover
= 365 ÷ =
2 Click competitor name to see calculations.
The average receivable collection period exhibited fluctuations over the five-year period. While generally remaining within a relatively narrow range, observable shifts indicate changes in the efficiency of collecting receivables.
- Average Receivable Collection Period
- The average receivable collection period decreased from 69 days in 2021 to 58 days in 2022, suggesting an improvement in the speed at which the company collects its receivables. This improvement could be attributed to more efficient credit and collection policies, or a change in customer payment terms.
- Following the improvement, the period increased slightly to 63 days in 2023, before returning to 58 days in 2024. This suggests the initial improvement was not fully sustained, but remained positive compared to the 2021 level.
- In 2025, the average collection period rose to 66 days. This represents the highest value observed during the analyzed period and may warrant further investigation to determine the underlying cause, such as extended payment terms offered to customers, or potential issues with collection efforts.
The fluctuations in the average receivable collection period should be considered in conjunction with the receivables turnover ratio to gain a more comprehensive understanding of the company’s credit and collection performance. A consistent upward trend in the collection period, as seen from 2024 to 2025, could potentially indicate a weakening in the quality of receivables or a slowdown in cash conversion.
Operating Cycle
| Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data | ||||||
| Average inventory processing period | ||||||
| Average receivable collection period | ||||||
| Short-term Activity Ratio | ||||||
| Operating cycle1 | ||||||
| Benchmarks | ||||||
| Operating Cycle, Competitors2 | ||||||
| AbbVie Inc. | ||||||
| Amgen Inc. | ||||||
| Bristol-Myers Squibb Co. | ||||||
| Danaher Corp. | ||||||
| Eli Lilly & Co. | ||||||
| Gilead Sciences Inc. | ||||||
| Johnson & Johnson | ||||||
| Pfizer Inc. | ||||||
| Regeneron Pharmaceuticals Inc. | ||||||
| Thermo Fisher Scientific Inc. | ||||||
| Vertex Pharmaceuticals Inc. | ||||||
| Operating Cycle, Sector | ||||||
| Pharmaceuticals, Biotechnology & Life Sciences | ||||||
| Operating Cycle, Industry | ||||||
| Health Care | ||||||
Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).
1 2025 Calculation
Operating cycle = Average inventory processing period + Average receivable collection period
= + =
2 Click competitor name to see calculations.
The operating cycle exhibited fluctuations over the five-year period. Initial observations indicate a decrease followed by a subsequent increase in the length of the cycle.
- Average Inventory Processing Period
- The average inventory processing period decreased significantly from 159 days in 2021 to 124 days in 2022. Following this reduction, the period experienced a moderate increase, reaching 144 days in 2023, 147 days in 2024, and stabilizing at 148 days in 2025. This suggests improved inventory management initially, with a leveling off in recent years.
- Average Receivable Collection Period
- The average receivable collection period demonstrated a similar pattern of decline and stabilization. A decrease was noted from 69 days in 2021 to 58 days in 2022. The period then rose slightly to 63 days in 2023, decreased again to 58 days in 2024, and concluded with an increase to 66 days in 2025. This indicates generally efficient collection practices, with a slight lengthening of the collection timeframe in the most recent year.
- Operating Cycle
- The operating cycle decreased from 228 days in 2021 to 182 days in 2022, reflecting the improvements in both inventory processing and receivable collection. The cycle then increased to 207 days in 2023, 205 days in 2024, and 214 days in 2025. The recent increases in the operating cycle correlate with the stabilization and slight increases observed in both the inventory processing and receivable collection periods, suggesting a potential slowdown in the overall efficiency of converting investments in inventory and receivables into cash.
Overall, the initial period demonstrated improvements in operating efficiency, but the most recent years show a trend towards a lengthening of the operating cycle, warranting further investigation into the underlying causes of these changes.
Average Payables Payment Period
| Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data | ||||||
| Payables turnover | ||||||
| Short-term Activity Ratio (no. days) | ||||||
| Average payables payment period1 | ||||||
| Benchmarks (no. days) | ||||||
| Average Payables Payment Period, Competitors2 | ||||||
| AbbVie Inc. | ||||||
| Amgen Inc. | ||||||
| Bristol-Myers Squibb Co. | ||||||
| Danaher Corp. | ||||||
| Eli Lilly & Co. | ||||||
| Gilead Sciences Inc. | ||||||
| Johnson & Johnson | ||||||
| Pfizer Inc. | ||||||
| Regeneron Pharmaceuticals Inc. | ||||||
| Thermo Fisher Scientific Inc. | ||||||
| Vertex Pharmaceuticals Inc. | ||||||
| Average Payables Payment Period, Sector | ||||||
| Pharmaceuticals, Biotechnology & Life Sciences | ||||||
| Average Payables Payment Period, Industry | ||||||
| Health Care | ||||||
Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).
1 2025 Calculation
Average payables payment period = 365 ÷ Payables turnover
= 365 ÷ =
2 Click competitor name to see calculations.
The analysis reveals a notable shift in the average payables payment period over the five-year period. Initially, the payables turnover exhibited an increase, subsequently influencing the payment period. A detailed examination of the average payables payment period and its relationship to payables turnover is presented below.
- Average Payables Payment Period
- The average payables payment period demonstrated a significant decrease from 123 days in 2021 to 89 days in both 2022 and 2023. This indicates an improvement in the company’s efficiency in settling its obligations to suppliers during these years. However, the period then increased to 98 days in both 2024 and 2025, suggesting a potential reversion towards longer payment terms or changes in supplier relationships.
- Payables Turnover
- Payables turnover increased from 2.96 in 2021 to 4.08 in 2022 and 4.11 in 2023. This suggests the company was more effectively managing its payables and making more frequent payments to suppliers. The ratio then decreased to 3.72 in 2024 and remained constant at 3.72 in 2025, indicating a stabilization, but a slight reduction in the rate at which payables are being paid off compared to the 2022-2023 levels.
The inverse relationship between payables turnover and the average payables payment period is evident. As payables turnover increased, the payment period decreased, and vice versa. The stabilization of payables turnover in the latter years corresponds with the stabilization of the average payables payment period. The increase in the payment period in 2024 and 2025 warrants further investigation to determine the underlying causes, such as potential negotiations with suppliers for extended payment terms or a shift in purchasing practices.
Cash Conversion Cycle
| Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | ||
|---|---|---|---|---|---|---|
| Selected Financial Data | ||||||
| Average inventory processing period | ||||||
| Average receivable collection period | ||||||
| Average payables payment period | ||||||
| Short-term Activity Ratio | ||||||
| Cash conversion cycle1 | ||||||
| Benchmarks | ||||||
| Cash Conversion Cycle, Competitors2 | ||||||
| AbbVie Inc. | ||||||
| Amgen Inc. | ||||||
| Bristol-Myers Squibb Co. | ||||||
| Danaher Corp. | ||||||
| Eli Lilly & Co. | ||||||
| Gilead Sciences Inc. | ||||||
| Johnson & Johnson | ||||||
| Pfizer Inc. | ||||||
| Regeneron Pharmaceuticals Inc. | ||||||
| Thermo Fisher Scientific Inc. | ||||||
| Vertex Pharmaceuticals Inc. | ||||||
| Cash Conversion Cycle, Sector | ||||||
| Pharmaceuticals, Biotechnology & Life Sciences | ||||||
| Cash Conversion Cycle, Industry | ||||||
| Health Care | ||||||
Based on: 10-K (reporting date: 2025-12-31), 10-K (reporting date: 2024-12-31), 10-K (reporting date: 2023-12-31), 10-K (reporting date: 2022-12-31), 10-K (reporting date: 2021-12-31).
1 2025 Calculation
Cash conversion cycle = Average inventory processing period + Average receivable collection period – Average payables payment period
= + – =
2 Click competitor name to see calculations.
The short-term operating activity of the company, as measured by key ratios, exhibits fluctuating trends over the five-year period. Generally, the company demonstrates a moderate cash conversion cycle, with variations observed in its inventory management, receivables collection, and payables disbursement practices.
- Average Inventory Processing Period
- The average time to process inventory initially decreased from 159 days in 2021 to 124 days in 2022, indicating improved inventory management efficiency. However, this improvement was not sustained, with the period increasing to 144 days in 2023 and remaining relatively stable at 147 and 148 days in 2024 and 2025, respectively. This suggests a potential stabilization of inventory processes after the initial gains, or possibly increased complexity in inventory holdings.
- Average Receivable Collection Period
- The average number of days to collect receivables decreased from 69 days in 2021 to 58 days in 2022, suggesting improved efficiency in collecting payments from customers. This trend continued to 63 days in 2023, before returning to 58 days in 2024. A slight increase to 66 days is observed in 2025. These fluctuations suggest some variability in customer payment behavior or changes in credit and collection policies.
- Average Payables Payment Period
- The average time taken to pay suppliers decreased significantly from 123 days in 2021 to 89 days in 2022, potentially reflecting improved cash management or renegotiated payment terms with suppliers. This period remained constant at 89 days in 2023, then increased to 98 days in both 2024 and 2025. This indicates a potential shift back towards longer payment terms, possibly to optimize working capital or due to supplier negotiations.
- Cash Conversion Cycle
- The cash conversion cycle initially decreased from 105 days in 2021 to 93 days in 2022, driven by improvements in both inventory processing and receivables collection, alongside a reduction in payables payment. The cycle then increased to 118 days in 2023, followed by a decrease to 107 days in 2024. A further increase to 116 days is observed in 2025. The overall trend suggests a cyclical pattern, with the cycle lengthening in 2023 and 2025, potentially indicating challenges in efficiently converting investments in inventory and receivables into cash.
In summary, while initial improvements were observed in operating efficiency, the company experienced fluctuations in its short-term activity ratios over the period. The cash conversion cycle demonstrates a degree of instability, warranting further investigation into the underlying drivers of these changes.